PurposeDiabetic macular edema (DME), a leading cause of visual impairment, can occur regardless of diabetic retinopathy (DR) stage. Poor metabolic control is hypothesized to contribute to DME development though large-scale studies have yet to identify such an association. This study aims to determine whether measurable markers of dysmetabolism associate with DME development in persons with diabetes. DesignRetrospective cohort study ParticipantsUsing data from the Sight Outcomes Research Collaborative (SOURCE) repository, patients with diabetes mellitus (DM) and no pre-existing DME were identified and followed over time to see what factors associated with DME development. MethodsCox proportional hazard modeling was used to assess the relationship between demographic variables, diabetes type, smoking history, baseline DR status, blood pressure (BP), lipid profile, body mass index (BMI), hemoglobin A1C (HbA1C) and new onset of DME. Main Outcome MeasuredAdjusted Hazard Ratio (HR) of developing DME with 95% confidence intervals. ResultsOf 47,509 eligible patients from 10 SOURCE sites (mean age 63±12 years, 58% female sex, 48% white race), 3633 (7.6%) developed DME in the study period. The mean±standard deviation time to DME was 875±684 days (∼2.4 years) with those with baseline NPDR (HR 3.67 95% [confidence interval (CI]):3.41-3.95) and PDR (HR 5.19 95% [CI]:4.61-5.85) more likely to develop DME. There was no difference in DME risk between type 1 and type 2 patients, however Black race was associated with a 40% increase in DME risk (HR 1.40 95% [CI]:1.30-1.51). Every one unit increase in HbA1C had a 15% increased risk of DME (HR 1.15 95% [CI]:1.13-1.17) and each 10 mmHg increase in systolic blood pressure associated with a 6% increased DME risk (HR 1.06 95% [CI]:1.02-1.09). No association was identified between DME development and BMI, triglyceride levels, or high-density lipoprotein levels. ConclusionsThese findings suggest that in patients with diabetes modifiable risk factors such as elevated HbA1C and blood pressure confer a higher risk for DME development, however other modifiable systemic markers of dysmetabolism such as obesity and dyslipidemia did not. Further work is needed to identify the underlying contributions of race in DME.
Read full abstract